Hormonal manipulation with letrozole in the treatment of metastatic malignant pericarcioma

P. Le MD,* A. Garg MD,* G. Brandao MD,† A. Abu-Sanad MD,* and L. Panasci MD*

1. INTRODUCTION

Perivascular epithelioid cell tumours (PE COMAs) are a group of rare mesenchymal neoplasms with a spectrum of clinical disease ranging from indolent to aggressive (“malignant pecoma”). There is a dearth of treatment options in advanced disease. Standard anthracycline- and gemcitabine-based chemotherapy regimens have yielded limited clinical activity. Inhibition of mtor (the mammalian target of rapamycin) has recently emerged as a new treatment strategy in malignant pecoma1,2. Here, we present a case of metastatic malignant pecoma with estrogen and progesterone receptor expression that showed a favourable and sustained response to letrozole.

2. CASE DESCRIPTION

In March 2007, a 54-year-old woman underwent resection of a large retroperitoneal malignant pecoma measuring 18×10×9 cm [Figure 1(A,B)]. A metastatic work-up, including thoracic, abdominal, and pelvic computed tomography imaging revealed 4 bilateral progressively enlarging lung nodules (largest: 1.8×1.7 cm).

In November 2008, the patient underwent a wedge resection to remove the 3 largest pulmonary nodules. Pathology examination of the lung nodules [Figure 1(C,D)] confirmed a metastatic sarcomatous tumour morphologically similar to the previously diagnosed intra-abdominal pecoma.

The patient was followed with serial imaging. In December 2010, computed tomography revealed progressive lung nodules, new axillary and retroperitoneal nodes, and an enlarging soft-tissue mass arising in the left chest wall and the left hemi-abdomen.

Between January and October 2011, the patient received palliative radiotherapy to the left chest wall soft-tissue mass with limited clinical benefit, followed by 6 cycles of liposomal doxorubicin, with an end result of disease progression. A brief period of disease stabilization from January 2012 to June 2012 was achieved with the mtor inhibitor sirolimus 4 mg daily, but disease progression soon followed, and sirolimus was discontinued.

Immunohistochemical examination of the original abdominal surgical specimen and the subsequently resected lung nodules showed that more than 90% of the tumour cells stained moderately-to-strongly positive for the estrogen and progesterone receptors [Figure 1(E,F)]. Letrozole 2.5 mg daily was initiated in August 2012 at a time when the patient’s condition had deteriorated, with the need for supplemental oxygen because of bulky intrathoracic disease with associated atelectasis. A clinical and radiologic partial response was noted by 12 weeks of treatment (Figure 2), and the need for supplemental oxygen ceased. Sixteen months after treatment initiation, the patient continued to derive clinical benefit from letrozole treatment.

3. DISCUSSION AND CONCLUSIONS

The pecoma family of tumours comprises angiomylipoma of the kidney, clear cell sugar tumour, lymphangioleiomyomatosis (LAM) of the lung, and also perivascular epithelioid cell tumour not otherwise
specified (PECOMA-nos), which are PECOMA tumours arising in non-classical anatomic locations. In contrast to renal angiomyolipoma and pulmonary LAM, which are generally considered benign tumours, some PECOMA tumours can exhibit frank malignant potential with an unpredictable clinical course.

Other tumours of the PECOMA family, such as renal angiomyolipoma and pulmonary LAM, show evidence of increased estrogen receptor, androgen receptor, and aromatase expression; however, the presence of hormone receptor expression in PECOMAS is not well reported in the literature. For example, in a large case series, estrogen and progesterone receptor testing was performed in only 3 of the 26 reported cases, and results were negative in all 3 cases. Although the prevalence of estrogen receptors in PECOMA is largely undefined, the female predominance of the disease suggests that hormone receptors might also be present in some PECOMAS. Furthermore, the common expression of estrogen and progesterone receptors in renal angiomyolipoma and pulmonary LAM, which share morphologic similarities with PECOMAS, suggest that this hormone pathway is a plausible target that should be pursued further in cases of malignant PECOMA.

In pulmonary LAM, several reports have described the successful use of hormone manipulation with a variety of modalities such as tamoxifen, oophorectomy, or luteinizing hormone–releasing hormone analogs. However, this therapeutic approach has not been widely reported or attempted in cases of PECOMA. In fact, only a single case report has detailed the use of hormone manipulation in the management of malignant PECOMA in the adjuvant setting, where response could not be documented.

The role of estrogen in PECOMAS is unclear. The original association of estrogen in the pathogenesis of pulmonary LAM was inferred based largely on the characteristics of the affected patients (namely, women of reproductive age); however, the mechanism by which estrogen is involved in the development of the disease remains uncertain to this day. Recently, an association has been identified between PECOMAS...
and tuberous sclerosis\textsuperscript{14}, an autosomal-dominant disease characterized by an inactivating mutation of a tumour suppressor gene, $TSC1$ or $TSC2$. In mice with tuberin (Tsc2)--null xenograft tumours, estrogen has been shown to increase the rates of pulmonary metastases and circulating tumour cells through activation of MEK-dependent pathways\textsuperscript{15}. In humans, estrogen might, through a similar mechanism, stimulate PECOMA tumour cells because of a mutation in the $TSC2$ tumour suppressor gene. Blocking estrogen might therefore inactivate the MEK pathway and provide a rationale for therapeutic efficacy. Aromatase inhibitors such as letrozole bind to aromatase, an enzyme that catalyzes the conversion of androgen to estrogen, effectively depleting circulating levels of estrogen in the body.

The dramatic response of our patient to letrozole suggests that patients with hormone-rich malignant PECOMAs might benefit from similar therapy.

4. CONFLICT OF INTEREST DISCLOSURES

The authors have no financial conflicts of interest to declare.

5. REFERENCES


Correspondence to: Lawrence Panasci, Department of Medical Oncology (E7), Jewish General Hospital, 3755 Cote-Sainte-Catherine Road, Montreal, Quebec H3T 1E2.

E-mail: lpanasci@hotmail.com

* Department of Medical Oncology, Jewish General Hospital (a McGill University affiliate), Montreal, QC.

† Department of Pathology, Jewish General Hospital (a McGill University affiliate), Montreal, QC.